Most Read Articles
5 days ago
Girls with eosinophilic oesophagitis (EoE) who show initial response to directed therapy will tend to continue to respond well to treatment, a recent study has shown.
Pearl Toh, 3 days ago
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
Elvira Manzano, 4 days ago
Final overall survival (OS) results from the double-blind phase III FLAURA study reinforce osimertinib as the standard frontline treatment for epidermal growth factor receptor-mutated (EGFRm) non–small cell lung cancer (NSCLC), say leading oncologists at ESMO 2019.
Tristan Manalac, 3 days ago
Babies born to mothers exposed to high levels of bisphenol A during pregnancy are at a greater risk of wheezing and poor lung function, according to a new study presented at the recently concluded International Congress of the European Respiratory Society (ERS 2019).

Etanercept does not increase incident uveitis in juvenile idiopathic arthritis

Jairia Dela Cruz
23 Jun 2018

Among children with juvenile idiopathic arthritis (JIA), the risk of developing uveitis is not greater in those treated with etanercept (ETN) than in those receiving methotrexate (MTX), according to a study presented at the European League Against Rheumatism (EULAR) 2018 Congress.

“This is reassuring given the reports of possible increased risk of uveitis among children with JIA receiving ETN,” the investigators said.

The study included 1,517 patients recruited to the BSPAR ETN* cohort study, among whom 1,009 (median age 11 years; 69 percent female) were on ETN and 508 (median age 9 years; 71 percent female) on MTX. Aside from being older, ETN-treated patients had longer disease duration (median, 3 vs 1 year) and were less likely to have persistent oligoarthritis (5 percent vs 17 percent).

New-onset uveitis occurred in 15 patients in the ETN cohort and 18 in the MTX cohort at a mean age of 8 and 5 years, respectively. The corresponding crude incidence rates were 0.6 and 2.4 per 100 person-years. [EULAR 2018, abstract OP0351]

Propensity-adjusted Cox regression showed that ETN reduced the risk of developing uveitis by 70 percent compared with MTX (hazard ratio, 0.30; 95 percent CI, 0.10–0.90). Factors such as age and gender, disease scores, disease duration, baseline steroid use, comorbidity, and International League of Associations for Rheumatology subtype were included in the analysis as potential confounders.

“Age appears to be a major influencing factor as patients in the MTX cohort were younger [and] thus at a higher risk of uveitis. For patients with a higher uveitis risk, other treatments options could have been selected, leading to possible confounding by indication, which in turn makes ETN look protective,” the investigators pointed out. “Researchers should take these selection biases into account when analysing their results.”

The present data suggest that a new diagnosis of uveitis is not more common among children with JIA receiving ETN vs MTX, despite taking into account differences in age and disease duration between the cohorts, the investigators said.

*British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Girls with eosinophilic oesophagitis (EoE) who show initial response to directed therapy will tend to continue to respond well to treatment, a recent study has shown.
Pearl Toh, 3 days ago
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
Elvira Manzano, 4 days ago
Final overall survival (OS) results from the double-blind phase III FLAURA study reinforce osimertinib as the standard frontline treatment for epidermal growth factor receptor-mutated (EGFRm) non–small cell lung cancer (NSCLC), say leading oncologists at ESMO 2019.
Tristan Manalac, 3 days ago
Babies born to mothers exposed to high levels of bisphenol A during pregnancy are at a greater risk of wheezing and poor lung function, according to a new study presented at the recently concluded International Congress of the European Respiratory Society (ERS 2019).